Welcome to Paid Research Studies




  • Condition:   Kidney Cancer
    Intervention:   Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
    Sponsor:   University Hospital, Bordeaux
    Recruiting

  • Condition:   Advanced Kidney Cancer
    Interventions:   Biological: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer;   Procedure: cryotherapy
    Sponsors:   Fuda Cancer Hospital, Guangzhou;   Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
    Recruiting

  • Condition:   Kidney Cancer
    Interventions:   Drug: NeoVax;   Drug: Ipilimumab
    Sponsors:   Patrick Ott, MD;   Bristol-Myers Squibb;   Oncovir, Inc.
    Recruiting

  • Condition:   Kidney Cancer
    Intervention:  
    Sponsor:   Zealand University Hospital
    Recruiting

  • Condition:   Renal Cancer
    Interventions:   Other: salvia for germline DNA;   Behavioral: the Kidney Cancer Questionnaire;   Behavioral: Family History Questionnaire (when applicable)
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Advanced Non-Clear Cell Kidney Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Atezolizumab
    Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.
    Recruiting

  • Condition:   Kidney Cancer
    Interventions:   Combination Product: CK2 and ATM inhibitors serine/ threonin Kinase combination;   Drug: Sunitinib;   Drug: Pazopanib;   Drug: Temsirolimus
    Sponsor:   University Hospital, Grenoble
    Recruiting

  • Condition:   Kidney Cancer
    Intervention:   Biological: cell infusion
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Loyola University Medical Center (LUMC)
    Recruiting

  • Conditions:   Advanced Kidney Cancer;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma
    Interventions:   Drug: Guadecitabine;   Drug: Durvalumab
    Sponsors:   Ajjai Alva, MD;   AstraZeneca;   Big Ten Cancer Research Consortium
    Recruiting

  • Condition:   Metastatic Kidney Cancer
    Intervention:   Biological: blood sample
    Sponsor:   University Hospital, Rouen
    Not yet recruiting

  • Condition:   Kidney Cancer
    Intervention:  
    Sponsor:   Zealand University Hospital
    Recruiting

  • Condition:   Renal Tumor
    Intervention:   Radiation: Stereotactic Ablative Radiotherapy
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Kidney Cancer Metastatic;   Kidney Cancer;   Kidney Cancer, Stage IV
    Interventions:   Drug: Nivolumab/Ipilimumab;   Radiation: SBRT
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Renal Cancers
    Intervention:   Radiation: Stereotactic Ablative Radiation Therapy
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Renal Cancer
    Intervention:   Procedure: Multiparametric MR imaging (mpMRI)
    Sponsor:   University Hospital, Bordeaux
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Intervention:   Behavioral: PRISM care program
    Sponsor:   Hospices Civils de Lyon
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Kidney Cancer
    Intervention:   Other: Non-Interventional
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Kidney Cancer
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab
    Sponsor:   Brian Rini
    Recruiting

  • Condition:   Clear Cell Metastatic Renal Cell Carcinoma
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Pazopanib;   Drug: Sunitinib
    Sponsor:   Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: High Dose IL-2;   Radiation: SBRT
    Sponsors:   Providence Health & Services;   Prometheus Laboratories;   Cytokine Working Group
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Intervention:   Drug: denosumab
    Sponsor:   Centre Leon Berard
    Recruiting

  • Conditions:   Renal Cell Carcinoma, Clear Cell;   Metastatic Kidney Cancer
    Intervention:   Drug: Pembrolizumab plus denosumab
    Sponsors:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   Merck Sharp & Dohme Corp.;   Amgen
    Recruiting

  • Condition:   Renal Cancer Metastatic
    Intervention:   Biological: Immunological and tumour characterization
    Sponsor:   Centre Leon Berard
    Recruiting

  • Condition:   Childhood Renal Tumor
    Interventions:   Drug: treatment Vincristin;   Drug: treatment Actinomycin-D;   Drug: treatment Doxorubicin;   Drug: treatment Carboplatin;   Drug: Etoposide
    Sponsor:   Assistance Publique Hopitaux De Marseille
    Not yet recruiting

  • Condition:   Renal Cancer
    Interventions:   Procedure: Robot;   Procedure: Cryoablation
    Sponsor:   Jørgen Bjerggaard Jensen
    Not yet recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Radiation: Stereotactic Ablative Body Radiosurgery (SABR);   Drug: Pembrolizumab
    Sponsor:   Peter MacCallum Cancer Centre, Australia
    Recruiting

  • Condition:   Renal Cancer Metastatic
    Intervention:   Drug: Nivolumab
    Sponsor:   Gruppo Oncologico Italiano di Ricerca Clinica
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Drug: TAK-228
    Sponsors:   Dana-Farber Cancer Institute;   Millennium: The Takeda Oncology Company
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma Treated With Cabozantinib
    Intervention:   Device: Usability of an electronic symptom management application
    Sponsors:   Duke University;   Exelixis
    Not yet recruiting

  • Condition:   Clear Cell Metastatic Renal Cell Carcinoma
    Intervention:   Radiation: Stereotactic radiotherapy
    Sponsors:   Sunnybrook Health Sciences Centre;   Pfizer
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: Pexastimogene Devacirepvec (Pexa-Vec);   Biological: REGN2810
    Sponsors:   SillaJen, Inc.;   Regeneron Pharmaceuticals
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Other: Ipilimumab placebo
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Device: CyberKnife
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Metastatic Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Ibrutinib;   Drug: Nivolumab
    Sponsors:   University of California, Davis;   Pharmacyclics LLC.
    Recruiting

  • Condition:   Renal Cancer
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Intervention:   Drug: Nivolumab
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Intervention:  
    Sponsors:   Pfizer;   TFS Trial Form Support
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer
    Interventions:   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Procedure: Nephrectomy
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Radiation: ARREST-study
    Sponsor:   UMC Utrecht
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
    Interventions:   Drug: Vandetanib;   Drug: Metformin;   Drug: Vandetanib/Metformin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Kidney Cancer
    Intervention:   Other: Active Surveillance
    Sponsor:   IRCCS San Raffaele
    Recruiting

  • Condition:   Renal Cell Carcinoma Metastatic
    Interventions:   Drug: Abemaciclib;   Drug: Sunitinib
    Sponsors:   Milton S. Hershey Medical Center;   Eli Lilly and Company
    Not yet recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   GlaxoSmithKline
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
    Interventions:   Biological: NKTR-214;   Drug: Sunitinib;   Biological: Nivolumab;   Drug: Cabozantinib
    Sponsors:   Nektar Therapeutics;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Metastatic Renal Cancer;   Stage III Renal Cell Cancer
    Intervention:   Drug: observance of oral drug treatment
    Sponsors:   Institut Cancerologie de l'Ouest;   University of Angers, GRANEM;   Fondation ARC
    Recruiting

  • Condition:   Clear Renal Cell Cancer (< 7cm Size)
    Intervention:   Procedure: Partial or radical nephrectomy
    Sponsor:   Yonsei University
    Recruiting

  • Condition:   Renal Cell Cancer
    Interventions:   Drug: Olaparib;   Drug: Cediranib;   Drug: Durvalumab
    Sponsors:   CCTU- Cancer Theme;   University of Cambridge;   AstraZeneca;   Cancer Research UK
    Not yet recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: RO6874281
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Renal Neoplasm With Metastasis;   Response Evaluation Criteria in Solid Tumors
    Intervention:  
    Sponsor:   University of Aarhus
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: CCT301-38;   Biological: CCT301-59
    Sponsors:   Shanghai Sinobioway Sunterra Biotech;   Shanghai Public Health Clinical Center
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Drug: CTT1057
    Sponsors:   Cancer Targeted Technology;   University of California, San Francisco
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Other: Routine care as per site standard.
    Sponsor:   iOMEDICO AG
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: lenvatinib;   Drug: everolimus
    Sponsor:   Eisai Inc.
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Pazopanib;   Drug: Abexinostat;   Other: Placebo
    Sponsor:   Xynomic Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Renal Tumor;   Wilms Tumor
    Intervention:   Other: Proton beam radiation using pencil beam scanning
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Conditions:   Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
    Intervention:   Drug: pazopanib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Renal Carcinoma Metastatic;   Kidney Neoplasms;   Renal Cancer
    Intervention:   Other: Electronic PRO in daily clinical practice
    Sponsor:   Centre Hospitalier Universitaire de Besancon
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   Chugai Pharmaceutical
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: lenvatinib;   Drug: everolimus;   Drug: pembrolizumab;   Drug: Sunitinib
    Sponsor:   Eisai Inc.
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: OTL38;   Device: Intraoperative fluorescence imaging system
    Sponsor:   Chandru Sundaram
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Lenvatinib;   Drug: Everolimus;   Procedure: Partial or Radical Cytoreductive Nephrectomy
    Sponsors:   Yousef Zakharia;   Eisai Research Institute
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Nivolumab;   Drug: Axitinib
    Sponsor:   Fox Chase Cancer Center
    Recruiting

  • Conditions:   Renal Tumor Histology;   Cutaneous Leiomyoma;   Kidney Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Other: Data collection
    Sponsor:   Ipsen
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Avelumab;   Drug: Cabozantinib
    Sponsors:   University of Utah;   EMD Serono
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Entinostat;   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Roberto Pili;   Bristol-Myers Squibb;   Syndax Pharmaceuticals;   Indiana University School of Medicine
    Recruiting

  • Condition:   Oligoprogressive Renal Cell Carcinoma
    Intervention:   Radiation: Stereotactic ablative body radiation (SABR)
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Diagnostic Test: Immunohistochemistry
    Sponsor:   Assiut University
    Not yet recruiting

  • Conditions:   Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
    Interventions:   Drug: CB-839;   Drug: Cabozantinib;   Drug: Placebo
    Sponsor:   Calithera Biosciences, Inc
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Sunitinib;   Drug: Bevacizumab
    Sponsor:   King Faisal Specialist Hospital & Research Center
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Procedure: endoscopic robot-assisted simple enucleation;   Procedure: standard robot-assisted partial nephrectomy
    Sponsor:   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Device: TDS-IM System;   Biological: Neoantigen DNA Vaccine;   Procedure: Research blood draw
    Sponsors:   Washington University School of Medicine;   MedImmune LLC
    Not yet recruiting

  • Conditions:   Metastatic Cancer;   Renal Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Entinostat
    Sponsors:   Roberto Pili;   Genentech, Inc.;   Syndax Pharmaceuticals
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: Nivolumab;   Drug: Cabozantinib;   Drug: Sunitinib;   Biological: Ipilimumab
    Sponsors:   Bristol-Myers Squibb;   Exelixis;   Ono Pharmaceutical Co. Ltd
    Recruiting

  • Condition:   Oligometastatic Renal Cell Carcinoma
    Intervention:   Radiation: Stereotactic ablative body radiation (SABR)
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Intervention:   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Renal Cell Cancer Metastatic
    Interventions:   Drug: CM082 combined with everolimus;   Drug: CM082;   Drug: Everolimus
    Sponsor:   AnewPharma
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: Pembrolizumab;   Drug: Placebo (saline solution)
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Aldesleukin;   Biological: Pembrolizumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Papillary Renal Cell Carcinoma
    Intervention:   Drug: INC280
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Pembrolizumab
    Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Intervention:   Drug: Cabometyx
    Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Recruiting

  • Condition:   Advanced Renal Cell Carcinoma
    Intervention:   Other: Carevive software
    Sponsor:   University of Rochester
    Not yet recruiting

  • Condition:   Melanoma; Renal Cell Carcinoma
    Interventions:   Other: Blood collection for laboratory studies;   Other: Data collection from medical record
    Sponsor:   Indiana University
    Recruiting

  • Condition:   Advanced Renal Cell Carcinoma
    Interventions:   Drug: Nivolumab 240 mg;   Drug: Ipilimumab 1mg/kg;   Drug: Nivolumab 3mg/kg;   Drug: Nivolumab 360mg
    Sponsors:   Michael B. Atkins, MD;   Bristol-Myers Squibb;   Hoosier Cancer Research Network
    Recruiting

  • Condition:   Clear Cell Renal Cell Carcinoma
    Interventions:   Drug: Sitravatinib;   Drug: Nivolumab
    Sponsor:   Mirati Therapeutics Inc.
    Recruiting

  • Condition:   Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
    Intervention:   Drug: Low dose of aspirin
    Sponsor:   RenJi Hospital
    Recruiting

  • Condition:   Renal Cell Carcinoma, Metastatic
    Interventions:   Drug: ESK981;   Drug: Nivolumab
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Kidney Neoplasms;   Kidney Cancer;   Pneumothorax;   FLCN Protien, Human
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Clear Cell Renal Carcinoma
    Intervention:   Drug: Sunitinib
    Sponsors:   Spanish Oncology Genito-Urinary Group;   Pfizer;   Apices Soluciones S.L.
    Recruiting

  • Conditions:   Diarrhea;   Metastatic Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Micronutrient-Fortified Probiotic Yogurt;   Drug: VEGF‐TKI
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Advanced or Metastatic Renal Cell Carcinoma
    Intervention:  
    Sponsor:   Ipsen
    Recruiting

  • Condition:   Metastatic Clear Cell Renal Cell Carcinoma
    Interventions:   Drug: Nivolumab;   Radiation: SAbR
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Conditions:   Metastatic Melanoma;   Renal Cell Carcinoma
    Interventions:   Drug: Nivolumab;   Drug: IL2
    Sponsor:   Mina Nikanjam
    Not yet recruiting

  • Conditions:   Malignant Neoplasms of Urinary Tract;   Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Sunitinib
    Sponsors:   M.D. Anderson Cancer Center;   Exelixis
    Recruiting

  • Condition:   Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
    Interventions:   Drug: cabozantinib;   Drug: nivolumab
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma;   Kidney Cancer;   Renal Carcinoma;   Kidney Cancer Metastatic
    Intervention:   Drug: Olaparib
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   AstraZeneca
    Not yet recruiting

  • Conditions:   Malignant Neoplasms of Urinary Tract;   Oligometastatic Renal Cell Carcinoma
    Intervention:   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Cancer;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sitravatinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Kidney Neoplasms
    Intervention:   Procedure: Partial nephrectomy
    Sponsors:   University of Sao Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Anti-OX40 Antibody PF-04518600;   Drug: Axitinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Kidney Neoplasms;   Surgical Oncology
    Intervention:   Device: 3D-models
    Sponsors:   Dr Eoin R Hyde;   National Institute for Health Research, United Kingdom;   Royal Free Hospital NHS Foundation Trust
    Not yet recruiting

  • Conditions:   Renal Cell Carcinoma Metastatic;   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   Ipsen
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Renal Cell Cancer;   Adenocarcinoma Of Kidney;   Adenocarcinoma, Renal Cell;   Kidney Cancer;   Cancer of the Kidney
    Intervention:   Other: Non-interventional
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
    Intervention:   Drug: SGI-110 (guadecitabine)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Kidney Cancer;   Breast Cancer
    Intervention:   Other: managment of oral therapy
    Sponsor:   Centre Georges Francois Leclerc
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Three-Dimensional;   Venous Thromboses
    Interventions:   Device: 3D printing + images;   Other: Images
    Sponsor:   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
    Not yet recruiting

  • Conditions:   Prostate Cancer;   Renal Cancer
    Intervention:   Drug: [68Ga]P16-093
    Sponsor:   Five Eleven Pharma, Inc.
    Recruiting

  • Conditions:   Metastatic Renal Cell Cancer;   Malignant Melanoma, Metastatic
    Intervention:   Other: Boost of radiotherapy + high dose IL-2 treatment
    Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
    Recruiting

  • Condition:   Small Renal Mass, Kidney Cancer
    Intervention:  
    Sponsor:   Yale University
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab
    Sponsors:   University College, London;   AstraZeneca;   Kidney Cancer UK
    Recruiting

  • Conditions:   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
    Intervention:   Biological: Nivolumab/Ipilimumab
    Sponsors:   AIO-Studien-gGmbH;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
    Interventions:   Drug: Selenomethionine (SLM);   Drug: Axitinib
    Sponsor:   Yousef Zakharia
    Recruiting

  • Conditions:   Melanoma;   Renal Cell Carcinoma;   Non-Small Cell Lung Cancer
    Intervention:   Drug: HBI-8000 in combination with nivolumab
    Sponsors:   HUYA Bioscience International;   Quintiles, Inc.
    Recruiting

  • Conditions:   Colorectal Cancer;   Gastroesophageal Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: Gevokizumab;   Drug: Bevacizumab;   Drug: Modified FOLFOX6;   Drug: FOLFIRI;   Drug: Ramucirumab;   Drug: Paclitaxel;   Drug: Cabozantinib
    Sponsor:   Novartis Pharmaceuticals
    Not yet recruiting

  • Conditions:   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Procedure: Arterial Spin Labeling Magnetic Resonance Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Perfusion Magnetic Resonance Imaging
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI);   Rutgers Cancer Institute of New Jersey
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Ascorbic Acid;   Drug: Pazopanib Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma
    Intervention:   Drug: Sunitinib
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Renal Cell Cancer
    Intervention:  
    Sponsors:   Washington University School of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   iOMEDICO AG
    Recruiting

  • Condition:   Kidney Neoplasm
    Intervention:  
    Sponsors:   Johns Hopkins University;   National Comprehensive Cancer Network
    Recruiting

  • Conditions:   Kidney Cancer;   Prostate Cancer
    Interventions:   Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;   Drug: 0.9% Sodium Chloride Injection
    Sponsor:   University of Missouri-Columbia
    Recruiting

  • Conditions:   RCC;   Clear Cell Renal Cell Carcinoma;   Kidney Cancer;   Renal Cancer;   Renal Cell Carcinoma;   Renal Cell Cancer Metastatic;   Renal Cell Carcinoma Recurrent;   Renal Cell Cancer, Recurrent;   Kidney
    Intervention:   Drug: PT2977 in combination with cabozantinib tablets
    Sponsor:   Peloton Therapeutics, Inc.
    Recruiting

  • Conditions:   Chronic Kidney Diseases;   Renal Tumor
    Intervention:   Other: Ultrasound Imaging
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting

  • Conditions:   Advanced Melanoma;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: APX005M;   Drug: Cabiralizumab;   Drug: Nivolumab
    Sponsors:   Yale University;   Bristol-Myers Squibb;   Apexigen, Inc.
    Recruiting

  • Conditions:   Healthy Subject;   Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
    Interventions:   Procedure: Computed Tomography;   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Imaging
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma;   Stage III Renal Cell Cancer American Joint Committee on Cancer AJCC v8;   Stage IV Renal Cell Cancer American Joint Committee on Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: CBM588;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   Ipsen
    Not yet recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Entinostat;   Drug: Interleukin-2
    Sponsors:   Roberto Pili;   Indiana University Melvin and Bren Simon Cancer Center;   Prometheus Laboratories;   Syndax Pharmaceuticals
    Recruiting

  • Condition:   Renal Cell Cancer Metastatic
    Intervention:   Drug: CT053PTSA
    Sponsor:   Sunshine Lake Pharma Co., Ltd.
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
    Interventions:   Procedure: Metastasectomy;   Procedure: Nephrectomy;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Clear Cell Renal Cell Carcinoma
    Intervention:   Drug: Sunitinib
    Sponsors:   Instituto do Cancer do Estado de São Paulo;   Pfizer
    Recruiting

  • Conditions:   Clear Cell Renal Cancer;   Circulating Tumor Cells;   Circulating Endothelial Cells;   Prognostic Biomarkers;   Predictive Biomarkers
    Intervention:   Other: None- observational study
    Sponsors:   Lawson Health Research Institute;   London Health Sciences Centre;   Hamilton Health Sciences Corporation
    Recruiting

  • Conditions:   Renal Cell Carcinoma, Metastatic;   Renal Cell Cancer, Recurrent
    Intervention:   Behavioral: Concomitant coaching
    Sponsors:   AIO-Studien-gGmbH;   Pfizer;   Celerion
    Recruiting

  • Condition:   Renal Cancer
    Interventions:   Device: Robotic-assisted partial nephrectomy;   Other: Open partial nephrectomy
    Sponsor:   Intuitive Surgical
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Renal Tumor
    Interventions:   Diagnostic Test: Blood sample;   Diagnostic Test: urine sample;   Diagnostic Test: Multi planar MRI
    Sponsor:   Odense University Hospital
    Recruiting

  • Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Oligometastasis;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
    Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Condition:   Cancer of Kidney
    Intervention:  
    Sponsor:   Centre Hospitalier Universitaire, Amiens
    Recruiting

  • Conditions:   Liver Cancer;   Kidney Cancer
    Interventions:   Device: Ablation;   Device: Biopsy
    Sponsor:   Western University, Canada
    Not yet recruiting

  • Conditions:   Von-Hippel Lindau;   Kidney Disease, Chronic
    Interventions:   Drug: Perflutren lipid microsphere;   Drug: Sulfur hexafluoride lipid microspheres
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Lantheus Medical Imaging;   Vanderbilt University
    Recruiting

  • Conditions:   Metastatic Renal Cell Cancer;   Recurrent Melanoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Radiation: Hypofractionated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Nelfinavir Mesylate;   Biological: Nivolumab;   Biological: Pembrolizumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Renal Cell Carcinoma (mRCC)
    Intervention:   Other: observational
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Renal Cancer
    Interventions:   Procedure: Robot assisted partial nephrectomy super-selective clamping;   Procedure: Robot assisted partial nephrectomy with renal artery clamping
    Sponsors:   University Hospital, Grenoble;   Clinical Investigation Centre for Innovative Technology Network;   Intuitive Surgical
    Recruiting

  • Conditions:   Renal Neoplasm;   Renal Injury
    Interventions:   Procedure: Remote Ischemic Preconditioning;   Procedure: Sham control
    Sponsor:   Seoul National University Hospital
    Recruiting

  • Conditions:   Small Renal Mass;   Kidney Tumor
    Interventions:   Procedure: Small Renal Mass Biopsy;   Other: No Small Renal Mass Biopsy
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Drug: PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
    Sponsors:   University of Wisconsin, Madison;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Kidney Wilms Tumor;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Kidney Wilms Tumor;   Stage II Renal Cell Cancer AJCC v7;   Stage III Kidney Wilms Tumor;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Kidney Wilms Tumor;   Stage IV Renal Cell Cancer AJCC v7;   Stage V Kidney Wilms Tumor
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Renal Cancer Metastatic
    Intervention:   Biological: Combinations treatment
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma Type 1;   Papillary Renal Cell Carcinoma Type 2;   Chromophobe Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Xp11 Translocation Carcinoma
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   TFE3 Gene Translocation;   TFEB Gene Translocation
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Kidney Cancer;   Urologic Malignant Disorders;   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hepatocellular Carcinoma;   Renal Cell Carcinoma
    Interventions:   Biological: APL-501;   Drug: APL-101;   Biological: Nivolumab
    Sponsors:   Apollomics (Australia) Pty. Ltd.;   Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.);   Novotech (Australia) Pty Limited
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Clear Cell Renal Cell Carcinoma
    Intervention:   Diagnostic Test: 89Zr-girentuximab
    Sponsor:   Telix International Pty Ltd
    Recruiting

  • Condition:   Malignant Neoplasms of Urinary Tract
    Intervention:   Drug: Daratumumab
    Sponsors:   M.D. Anderson Cancer Center;   Janssen Research & Development, LLC
    Recruiting

  • Condition:   Carcinoma, Renal Cell
    Intervention:   Drug: Sunitinib
    Sponsor:   Duke University
    Recruiting

  • Condition:   Renal Malignant Tumor
    Intervention:   Other: Contrast enhanced ultrasound
    Sponsor:   Indiana University
    Not yet recruiting

  • Condition:   Clear Cell Renal Cell Carcinoma
    Intervention:   Drug: Axitinib Oral Tablet [Inlyta]
    Sponsors:   University of California, San Diego;   The Cleveland Clinic
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Radiation: Stereotactic ablative radiation therapy
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Drug: Avelumab
    Sponsors:   The Netherlands Cancer Institute;   Pfizer
    Recruiting

  • Conditions:   HLRCC;   Metastatic Papillary RCC
    Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Procedure: Non-renorrhaphy;   Procedure: Renorrhaphy
    Sponsor:   Indiana University
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Intervention:   Other: questionnaire
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Mucositis
    Interventions:   Drug: Folic Acid;   Drug: Placebo Oral Tablet
    Sponsor:   Frede Donskov
    Recruiting

  • Condition:   Collecting Duct Carcinoma (Kidney)
    Intervention:   Drug: cabozantinib
    Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Recruiting

  • Conditions:   Carcinoma, Renal Cell;   Melanoma
    Interventions:   Drug: Pembrolizumab;   Drug: Interleukin-2
    Sponsor:   William Grosh, MD
    Recruiting

  • Condition:   Advanced Cancer
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Relatlimab;   Drug: BMS-986205;   Drug: BMS-813160
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Condition:   Advanced Renal Cell Carcinoma
    Intervention:   Drug: Axitinib
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Carcinoma, Renal Cell
    Intervention:   Device: Fitbit Versa
    Sponsors:   University of Texas Southwestern Medical Center;   Simmons Cancer Center
    Not yet recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Melanoma;   Non-small Cell Lung Cancer
    Interventions:   Drug: CB-839;   Drug: Nivolumab
    Sponsor:   Calithera Biosciences, Inc
    Recruiting

  • Condition:   Carcinoma, Renal Cell
    Intervention:  
    Sponsor:   Pfizer
    Not yet recruiting

  • Condition:   Carcinoma, Renal Cell
    Interventions:   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Procedure: Microwave Ablation (MWA)
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Carcinoma, Renal Cell
    Intervention:  
    Sponsors:   Chalmers University of Technology;   Sahlgrenska University Hospital, Sweden;   University of Modena and Reggio Emilia
    Recruiting

  • Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage I Prostate Cancer;   Stage I Renal Cell Cancer;   Stage II Bladder Urothelial Carcinoma;   Stage II Renal Cell Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Procedure: Radical Cystectomy;   Biological: Recombinant EphB4-HSA Fusion Protein;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Clear-Cell Metastatic Renal Cell Carcinoma;   Non Small Cell Lung Cancer Metastatic;   Brain Metastases, Adult
    Interventions:   Drug: Nivolumab;   Radiation: Radiosurgery
    Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Bristol-Myers Squibb
    Recruiting

  • Condition:   Carcinoma, Renal Cell
    Intervention:  
    Sponsors:   Chalmers University of Technology;   Sahlgrenska University Hospital, Sweden;   University of Modena and Reggio Emilia
    Recruiting

  • Conditions:   Carcinoma, Renal Cell, Advanced;   Lymphoma, Mantle-Cell;   Gastrointestinal Stroma Tumors
    Interventions:   Drug: Temsirolimus;   Drug: Sunitinib;   Drug: Axitinib
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Complete Remission in Renal Cell Carcinoma
    Intervention:   Drug: sunitinib
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Non-squamous, Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and Ovarian Cancer (OC)
    Intervention:   Drug: Sitravatinib Tislelizumab
    Sponsor:   BeiGene
    Not yet recruiting

  • Condition:   Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
    Interventions:   Biological: PDR001;   Drug: LCL161;   Drug: Everolimus;   Drug: Panobinostat;   Drug: QBM076;   Drug: HDM201
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Malignant Melanoma, Metastatic;   Non Small Cell Lung Cancer Metastatic;   Kidney Cancer Metastatic
    Intervention:   Drug: EVAX-01-CAF09b
    Sponsor:   Herlev Hospital
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Urinary Bladder Neoplasms
    Interventions:   Drug: Pembrolizumab;   Drug: Vorinostat
    Sponsor:   Roberto Pili
    Recruiting

  • Conditions:   Carcinoma, Renal Cell;   Renal Malignant Tumor;   Renal Cyst;   Renal Tumor
    Intervention:   Procedure: partial nephrectomy
    Sponsor:   Salzburger Landeskliniken
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma Type 1;   Papillary Renal Cell Carcinoma Type 2;   Chromophobe Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Xp11.2 Translocation-Related Renal Cell Carcinoma
    Intervention:   Drug: Cabozantinib
    Sponsor:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group
    Recruiting

  • Conditions:   Metastatic Renal Cell Carcinoma;   Metastatic Urothelial Carcinoma
    Interventions:   Drug: Nivolumab;   Drug: Atezolizumab;   Radiation: Radiation & immunotherapy
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   RCC;   Metastatic Renal Cell Carcinoma
    Intervention:   Biological: Immunological and tumour characterization
    Sponsor:   National Cancer Institute, Naples
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Urothelial Carcinoma;   Cervical Cancer;   Ovarian Cancer Recurrent;   Endometrial Cancer
    Interventions:   Biological: SHR-1210;   Drug: Famitinib
    Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
    Recruiting

  • Conditions:   Adult Polycystic Kidney Disease;   Kidney Neoplasms;   Kidney Dysfunction
    Intervention:   Diagnostic Test: sinistrin clearance dynamic measurement
    Sponsor:   Thomas Mueller
    Recruiting

  • Conditions:   Genito Urinary Cancer;   Bladder Cancer;   Kidney Cancer;   Prostate Cancer
    Intervention:   Procedure: Bone marrow biopsy
    Sponsor:   Duke University
    Recruiting

  • Conditions:   Kidney Medullary Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Ixazomib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Prostate Cancer Stage I;   Kidney Cancer Stage I;   Bladder Cancer Stage II;   Prostate Cancer Stage II
    Intervention:   Behavioral: Patient-centered communication of life expectancy
    Sponsor:   Cedars-Sinai Medical Center
    Not yet recruiting

  • Conditions:   Urothelial Carcinoma;   Kidney Cancer;   Ureter Cancer;   Bladder Cancer
    Interventions:   Drug: Denosumab;   Other: Denosumab Placebo;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Dietary Supplement: Calcium;   Dietary Supplement: Vitamin D
    Sponsors:   University Health Network, Toronto;   Amgen
    Recruiting

  • Conditions:   Neoplasm Malignant;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer
    Intervention:   Drug: XL092
    Sponsor:   Exelixis
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Hypertension;   Melanoma
    Intervention:   Diagnostic Test: Ambulatory Blood Pressure Measurement
    Sponsor:   Vanderbilt University Medical Center
    Not yet recruiting

  • Conditions:   Renal Cell Carcinoma;   Lung Carcinoma;   Cervical Carcinoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasms;   Hereditary Neoplastic Syndromes;   Kidney Cancer;   Renal Cancer;   Bladder Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Locally Advanced or Metastatic Solid Tumours
    Intervention:   Drug: VB10.NEO
    Sponsor:   Vaccibody AS
    Recruiting

  • Conditions:   Breast Cancer;   Colorectal Cancer;   Kidney Cancer;   Lung Cancer;   Prostate Cancer;   Sarcoma;   Ovarian Cancer;   Lymphoma
    Interventions:   Other: Consultation, evaluation questionnaire;   Other: Geriatric consultation, evaluation questionnaire
    Sponsors:   Institut Bergonié;   Fondation Université de Bordeaux;   AG2R La Mondiale
    Recruiting

  • Conditions:   Mesothelioma;   Uveal Melanoma;   Renal Cell Carcinoma;   Cholangiocarcinoma
    Intervention:   Drug: Niraparib
    Sponsors:   University of Florida;   Tesaro, Inc.
    Recruiting

  • Conditions:   Cervical Cancer;   Renal Cancer;   Urothelial Cancer;   Melanoma;   Breast Cancer
    Interventions:   Biological: Anti-MAGE-A3-DP4 TCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: high dose Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Renal Cell Cancer;   Breast Cancer;   Melanoma;   Ovarian Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer (NSCLC);   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer;   Kidney Cancer;   Kidney Neoplasms;   Renal Cancer;   Renal Neoplasms
    Intervention:   Drug: Nivolumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Colorectal Cancer;   Bladder Cancer;   Prostate Cancer;   Kidney Cancer;   Advanced Sarcoma
    Interventions:   Other: Memory structuring intervention + Vagal breathing;   Other: support and attention (usual care)
    Sponsors:   Centre Oscar Lambret;   SCALab UMR CNRS 9193 Université de Lille
    Recruiting

  • Conditions:   Lymphoma;   Leukemia;   Multiple Myeloma;   Colon Cancer;   Renal Cancer
    Intervention:  
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Montefiore Medical Center;   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Glioblastoma Multiforme;   Gliosarcoma;   Colorectal Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: INC280;   Biological: bevacizumab
    Sponsors:   SCRI Development Innovations, LLC;   Novartis
    Recruiting

  • Conditions:   Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Renal Cell Carcinoma (RCC);   Urothelial Carcinoma;   Gastric Adenocarcinoma;   Colorectal Adenocarcinoma (CRC)
    Interventions:   Drug: ibrutinib;   Drug: everolimus;   Drug: docetaxel;   Drug: paclitaxel;   Drug: cetuximab
    Sponsor:   Pharmacyclics LLC.
    Recruiting

  • Condition:   Metastatic sRCC
    Interventions:   Drug: Avelumab;   Drug: Gemcitabine
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Non Small Cell Lung Cancer;   Metastatic Melanoma;   Metastatic Renal Cell Carcinoma;   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: IL-2;   Drug: Pembrolizumab;   Radiation: Radiotherapy
    Sponsors:   Arta Monjazeb;   Merck Sharp & Dohme Corp.
    Not yet recruiting

  • Conditions:   Breast Cancer;   Bladder Cancer;   Kidney Cancer;   Colon Cancer;   Prostate Cancer;   Lung Cancer;   Ovarian Cancer
    Intervention:   Genetic: PCR/PCR/LDR Strategy
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Columbia University;   Weill Medical College of Cornell University;   Icahn School of Medicine at Mount Sinai
    Recruiting

  • Conditions:   Bladder Cancer;   Colorectal Cancer;   Endometrial Cancer;   Kidney Cancer;   Skin Cancer;   Uterus Cancer
    Intervention:   Behavioral: Health and Diet Questionnaire
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Gastric Cancer;   Esophageal Cancer;   Lung Cancer;   Renal Cancer;   Oral Cancer
    Interventions:   Biological: Mogamulizumab;   Biological: Nivolumab
    Sponsors:   Osaka University;   Kyowa Hakko Kirin Co., Ltd;   Ono Pharmaceutical Co. Ltd;   Clinical Study Support, Inc.;   Fiverings Co., Ltd.
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: Cancer macrobead placement in abdominal cavity
    Sponsor:   The Rogosin Institute
    Recruiting

  • Conditions:   Von Hippel-Lindau Disease;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Birt-Hogg-Dube Syndrome;   SDHB Gene Mutation
    Intervention:  
    Sponsors:   Ilene Sussman, PhD;   National Organization for Rare Disorders
    Recruiting

  • Conditions:   Metastatic Cancer;   Melanoma Cancer;   Lung Cancer;   Bladder Cancer;   Renal Cancer;   Head/Neck Cancers
    Interventions:   Radiation: Stereotactic Body Radiotherapy;   Biological: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Advanced Solid Tumors;   Solid Tumor;   Solid Carcinoma;   Solid Tumor, Adult;   ccRCC;   RCC, Clear Cell Adenocarcinoma;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma, Metastatic;   Renal Cell Carcinoma Recurrent;   Renal Cell Carcinoma, Clear Cell Adenocarcinoma;   Glioblastoma;   Glioblastoma, Adult;   GBM;   Glioblastoma Multiforme
    Intervention:   Drug: PT2977
    Sponsor:   Peloton Therapeutics, Inc.
    Recruiting

  • Conditions:   Metastatic Non-small Cell Lung Cancer;   Locally Advanced Urothelial Cancer;   Metastatic Urothelial Cancer;   Unresectable Melanoma;   Metastatic Melanoma;   Locally Advanced Renal Cell Carcinoma;   Metastatic Clear-Cell Renal Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Melanoma;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Urothelial Carcinoma;   Triple Negative Breast Cancer
    Interventions:   Drug: Combination of NKTR-214 + nivolumab;   Drug: Combination of NKTR-214 + nivolumab + ipilimumab
    Sponsors:   Nektar Therapeutics;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Melanoma;   Renal Cell Carcinoma;   Non-small Cell Lung Cancer;   Head and Neck Cancer
    Interventions:   Drug: Pembrolizumab or Nivolumab;   Radiation: SBRT
    Sponsors:   University Hospital, Ghent;   GZA Ziekenhuizen Campus Sint-Augustinus;   AZ Sint-Lucas
    Recruiting

  • Conditions:   Bladder Small Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Metastatic Renal Cell Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma AJCC v6 and v7;   Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Penile Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IIIa Penile Cancer AJCC v7;   Stage IIIb Penile Cancer AJCC v7;   Stage IV Bladder Adenocarcinoma AJCC v7;   Stage IV Bladder Squamous Cell Carcinoma AJCC v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cutaneous Melanoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Urothelial Carcinoma;   Renal Cell Carcinoma
    Interventions:   Biological: GEN-009 Adjuvanted Vaccine;   Drug: Nivolumab
    Sponsor:   Genocea Biosciences, Inc.
    Recruiting

  • Conditions:   Platinum Resistant Ovarian Cancer;   Non Small Cell Lung Cancer Metastatic;   Papillary Renal Cell Carcinoma;   Papillary Thyroid Cancer;   Salivary Gland Cancer
    Intervention:   Drug: XMT-1536
    Sponsors:   Mersana Therapeutics;   Novella Clinical
    Recruiting

  • Conditions:   Metastatic Solid Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Non-small Cell Lung Cancer;   Melanoma;   Head and Neck Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Renal Cell Carcinoma;   Urothelial Carcinoma;   Esophageal Adenocarcinoma
    Intervention:   Drug: INBRX-105 - PDL1x41BB antibody
    Sponsor:   Inhibrx, Inc.
    Recruiting

  • Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Cell Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Plasmacytoid Urothelial Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Sarcomatoid Urothelial Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Locally Advance Pancreatic Ductal Adenocarcinoma;   Locally Advanced Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Metastatic Renal Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Stage III Pancreatic Cancer AJCC v8;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: ATR Kinase Inhibitor AZD6738;   Drug: Olaparib
    Sponsor:   University of California, San Francisco
    Recruiting

  • Conditions:   Lymphoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Bladder Carcinoma;   Recurrent Classical Hodgkin Lymphoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Renal Cell Carcinoma;   Stage III Bladder Cancer;   Stage III Lymphoma;   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage III Renal Cell Cancer;   Stage III Skin Melanoma;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Skin Melanoma;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Lymphoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Bladder Cancer;   Stage IVB Bladder Cancer;   Unresectable Head and Neck Squamous Cell Carcinoma;   Unresectable Solid Neoplasm
    Interventions:   Drug: Enzyme Inhibitor Therapy;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Pembrolizumab
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer, All Types;   Cancer of Liver;   Cancer of Stomach;   Cancer of Head and Neck;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Colon;   Cancer Skin;   Cancer of Cervix;   Cancer, Metastatic;   Cancer of Larynx;   Cancer of Neck;   Cancer of Lung;   Cancer of Brain and Nervous System;   Cancer of Vulva, Disseminated;   Cancer of Pancreas;   Sarcoma;   GIST;   Small-cell Lung Cancer;   Adenocarcinoma Lung;   Cancer of Prostate;   Cancer, Advanced;   Adrenal Cancer;   Testicular Cancer;   Uterine Cancer;   Bronchoalveolar Cell Lung Cancer;   Cancer Unknown Primary;   Glioblastoma Multiforme;   Oligodendroglioma;   Breast Cancer;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Cholangiocarcinoma;   Squamous Cell Carcinoma;   Transitional Cell Carcinoma;   Cancer, Other;   Cancer, Anal;   Melanoma;   Cancer, Bile Duct;   Cancer, Bladder;   Cancer Cords Vocal;   Cancers Cell Neuroendocrine;   Cancer Differentiated Poorly;   Cancer, Anaplastic Thyroid
    Intervention:  
    Sponsors:   SpeciCare;   Dana-Farber Cancer Institute;   Kalispell Regional Medical Center;   Georgia Institute of Technology;   Ontario Institute for Cancer Research;   SEngine Precision Medicine;   Helomics
    Recruiting

  • Conditions:   Gastric Cancer;   Esophageal Cancer;   Renal Cancer;   Prostate Cancer;   Bladder Cancer;   Pancreatic Cancer
    Interventions:   Device: ReCIVA;   Device: CASPER
    Sponsors:   Owlstone Ltd;   Cambridge University Hospitals NHS Foundation Trust;   Cancer Research UK
    Recruiting

  • Conditions:   Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
    Intervention:   Drug: 177Lu-J591
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Renal Cell Cancer;   Colorectal Cancer;   Triple Negative Breast Cancer;   Cervical Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Endometrial Cancer;   Sarcoma;   Squamous Cell Carcinoma of the Head and Neck;   Bladder Cancer;   Metastatic Castration Resistant Prostate Cancer;   Non-hodgkin Lymphoma
    Interventions:   Drug: CPI-006;   Drug: CPI-006 + CPI-444;   Drug: CPI-006 + pembrolizumab
    Sponsor:   Corvus Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting

  • Conditions:   Ewing Sarcoma;   Rhabdomyosarcoma;   Wilms Tumor;   Osteosarcoma;   Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos;   Renal Tumor;   Rhabdoid Tumor;   Clear Cell Renal Cell Carcinoma;   Sarcoma;   Sarcoma, Ewing;   Soft Tissue Sarcoma
    Intervention:   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Conditions:   Breast Cancer;   Lung Cancer;   Hepatocellular Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Renal Cancer
    Interventions:   Drug: NIS793;   Drug: PDR001
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Cancer;   Breast Cancer;   Lung Cancer;   Colon Cancer;   Ovarian Cancer;   Melanoma;   Lymphoma;   Leukemia;   Mutation;   Lynch Syndrome;   Cowden Syndrome;   BRCA1 Mutation;   BRCA2 Mutation;   Uterine Cancer;   Myeloma;   Kidney Cancer;   Head and Neck Cancer;   Meningioma
    Intervention:  
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Malignant Melanoma;   Renal Cell Cancer;   Triple Negative Breast Cancer;   Colorectal Cancer;   Bladder Cancer;   Metastatic Castration Resistant Prostate Cancer
    Interventions:   Drug: CPI-444;   Drug: CPI-444 + atezolizumab
    Sponsors:   Corvus Pharmaceuticals, Inc.;   Genentech, Inc.
    Recruiting

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting

  • Conditions:   Malignant Solid Neoplasm;   Metastatic Kidney Carcinoma;   Metastatic Melanoma;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Carcinoma;   Refractory Melanoma;   Sarcoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Biological: Pembrolizumab;   Biological: Ziv-Aflibercept
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Radiation Therapy;   Cancer;   Cancer of Anus;   Cancer of Bladder;   Cancer of Cervix;   Cancer of Colon;   Cancer of Rectum;   Cancer of Esophagus;   Cancer of Gallbladder;   Cancer of Liver;   Cancer of Ovary;   Cancer of Pancreas;   Cancer of Prostate;   Cancer of Kidney and Renal Pelvis;   Cancer of Stomach;   Cancer of Testis;   Cancer of Uterus;   Cancer of Uterus and Cervix;   Cancer of Kidney
    Intervention:  
    Sponsors:   DxTerity Diagnostics;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Non-small Cell Lung Cancer;   Breast Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Ovarian Cancer;   Cholangiocarcinoma;   Bladder Urothelial Carcinoma;   Pancreatic Adenocarcinoma;   Colorectal Cancer;   Esophageal Cancer;   Hepatic Cancer;   Head and Neck Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Other Solid Tumors;   Diffuse Large B-cell Lymphoma (DLBCL);   Mantle Cell Lymphoma;   Indolent B-cell Lymphomas;   Non-Hodgkin Lymphoma
    Interventions:   Drug: CDX-1140;   Drug: CDX-301
    Sponsor:   Celldex Therapeutics
    Recruiting

  • Conditions:   Glioma;   Lymphoma;   Metastatic Malignant Solid Neoplasm;   Neuroendocrine Neoplasm;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Colorectal Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Pancreatic Carcinoma;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage III Breast Cancer AJCC v7;   Stage III Colorectal Cancer AJCC v7;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Lung Cancer AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage III Prostate Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIA Colorectal Cancer AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIB Colorectal Cancer AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IIIC Colorectal Cancer AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Colorectal Cancer AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IV Lung Cancer AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IV Prostate Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7;   Unresectable Solid Neoplasm
    Interventions:   Other: Pharmacological Study;   Drug: Romidepsin
    Sponsors:   National Cancer Institute (NCI);   Celgene Corporation
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Cervical Carcinoma;   Pancreatic Carcinoma;   Triple Negative Breast Cancer;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Nasopharyngeal Carcinoma;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Non-small Cell Lung Carcinoma;   Small Cell Lung Carcinoma;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Advanced or Metastatic Solid Tumors
    Interventions:   Biological: XmAb®22841;   Biological: Pembrolizumab (Keytruda®)
    Sponsors:   Xencor, Inc.;   ICON plc
    Not yet recruiting

  • Conditions:   Melanoma (Excluding Uveal Melanoma);   Cervical Carcinoma;   Pancreatic Carcinoma;   Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Nasopharyngeal Carcinoma;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Non-small Cell Lung Carcinoma;   Small Cell Lung Cancer;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Advanced Solid Tumors
    Intervention:   Biological: XmAb®23104
    Sponsors:   Xencor, Inc.;   ICON plc
    Not yet recruiting

  • Conditions:   Melanoma;   Breast Carcinoma;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Non-small Cell Lung Carcinoma;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Endometrial Carcinoma;   Mesothelioma;   Neuroendocrine Carcinoma;   Cervical Cancer;   Small Cell Lung Carcinoma;   Squamous Cell Carcinoma of the Anus
    Intervention:   Biological: XmAb20717
    Sponsors:   Xencor, Inc.;   ICON plc
    Recruiting

  • Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
    Intervention:   Drug: Entrectinib
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Urothelial Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Melanoma;   Renal Cell Carcinoma;   Gastric Cancer;   Cervical Cancer;   Hepatocellular Carcinoma;   Microsatellite Instability;   Mismatch Repair Deficiency;   Colorectal Cancer
    Interventions:   Drug: ALT-803 + Pembrolizumab;   Drug: ALT-803 + Nivolumab;   Drug: ALT-803 + Atezolizumab;   Drug: ALT-803 + Avelumab
    Sponsor:   Altor BioScience
    Recruiting

  • Conditions:   Oncology;   Solid Tumor;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Melanoma;   Bladder Cancer
    Interventions:   Drug: MRx0518;   Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
    Sponsors:   4D pharma plc;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Neoplasms;   Melanoma;   Non Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Renal Cell Carcinoma;   Urothelial Neoplasm
    Interventions:   Drug: DSP-7888 Dosing Emulsion;   Drug: Nivolumab;   Drug: Atezolizumab
    Sponsor:   Boston Biomedical, Inc
    Recruiting

  • Conditions:   Solid Tumor;   Advanced Cancer;   Renal Cancer;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   NSCLC;   Lung Cancer
    Intervention:   Drug: APL-101 Oral Capsules (formerly CBT-101)
    Sponsor:   Apollomics Inc.
    Recruiting

  • Conditions:   Cancer;   Breast Cancer;   Gastric Cancer;   Renal Cancer;   Prostate Cancer;   Melanoma;   Lung Cancer;   Hepatocellular Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Glioblastoma;   Endometrial Cancer;   Bladder Cancer;   Esophageal Cancer;   B-cell Lymphoma
    Intervention:   Other: Blood draws
    Sponsor:   Hospices Civils de Lyon
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer (NSCLC);   Triple Negative Breast Cancer (TNBC);   Pancreatic Ductal Adenocarcinoma (PDAC);   Colorectal Cancer Microsatellite Stable (MSS);   Ovarian Cancer;   Renal Cell Carcinoma (RCC)
    Interventions:   Other: NZV930;   Other: PDR001;   Drug: NIR178
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
    Interventions:   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis;   Drug: Anti-seizure prophylaxis;   Drug: Ursodiol
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Cancer;   Lymphoma;   Pancreatic Cancer;   Glioblastoma Multiforme;   Sarcoma;   Breast Cancer;   Bladder Cancer;   Renal Cancer;   Ovarian Cancer;   Refractory Cancer;   Refractory Neoplasm;   Refractory Non-Hodgkin Lymphoma;   Refractory Brain Tumor;   Pancreatic Adenocarcinoma;   Resistant Cancer;   Neoplasm Metastasis;   Neoplasm of Bone;   Neoplasm, Breast;   Neoplasm of Lung;   Neoplasms,Colorectal;   Neoplasms Pancreatic;   Malignant Glioma;   Malignancies;   Malignancies Multiple;   Bone Metastases;   Bone Neoplasm;   Bone Cancer;   Pancreas Cancer;   Pancreatic Neoplasms;   Breast Neoplasms
    Interventions:   Drug: 9-ING-41;   Drug: Gemcitabine - 21 day cycle;   Drug: Doxorubicin.;   Drug: Lomustine;   Drug: Carboplatin.;   Drug: Nab paclitaxel.;   Drug: Paclitaxel.;   Drug: Gemcitabine - 28 day cycle
    Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium
    Recruiting

  • Conditions:   Melanoma;   Non-Small Cell Lung Cancer;   Bladder Cancer;   Colorectal Cancer;   Triple Negative Breast Cancer;   Renal Cancer;   Head and Neck Cancer;   Other Solid Cancers
    Interventions:   Drug: RO7198457;   Drug: Atezolizumab
    Sponsors:   Genentech, Inc.;   Biontech RNA Pharmaceuticals GmbH
    Recruiting

  • Conditions:   Cancer, Metastatic;   Cancer;   Cancer of Pancreas;   Cancer of Liver;   Cancer of Stomach;   Cancer Liver;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Cervix;   Cancer of Colon;   Cancer of Larynx;   Cancer, Lung;   Cancer, Breast;   Cancer, Advanced;   Cancer Prostate;   Cancer of Neck;   Cancer of Skin;   Neuroendocrine Tumors;   Carcinoma;   Mismatch Repair Deficiency;   BRCA Gene Rearrangement;   Non Hodgkin Lymphoma;   Leukemia;   Non Small Cell Lung Cancer;   Cholangiocarcinoma;   Glioblastoma;   Central Nervous System Tumor;   Melanoma;   Urothelial Carcinoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Testicular Cancer;   Breast Cancer
    Intervention:   Other: Clinical Trial Matching
    Sponsor:   Massive Bio, Inc.
    Recruiting

  • Conditions:   Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer;   Testicular Cancer;   Solid Tumor
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC
    Sponsors:   Ludwig Institute for Cancer Research;   MedImmune LLC;   Cancer Research Institute, New York City
    Recruiting

  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Hepatoma;   Gastric Cancer;   Pancreatic Cancer;   Mesothelioma;   Colorectal Cancer;   Esophagus Cancer;   Lung Cancer;   Glioma;   Melanoma;   Synovial Sarcoma;   Ovarian Cancer;   Renal Carcinoma
    Intervention:   Biological: CAR-T cell immunotherapy
    Sponsors:   Shenzhen BinDeBio Ltd.;   The First Affiliated Hospital of Zhengzhou University
    Recruiting

  • Conditions:   Pheochromocytoma;   Paraganglioma;   Inherited Cancer Syndrome;   Associated Conditions;   Kidney Neoplasms;   Bone Cancer;   Thyroid Neoplasms;   Other Cancer
    Intervention:   Genetic: Genetic screening
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Renal Cell Carcinoma;   Non-Small Cell Lung Cancer;   Castration-resistant Prostate Cancer;   Triple Negative Breast Cancer;   Ovarian Cancer;   Endometrial Cancer;   Hepatocellular Carcinoma;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Colorectal Cancer;   Head and Neck Cancer;   Differentiated Thyroid Cancer
    Interventions:   Drug: cabozantinib;   Drug: atezolizumab
    Sponsor:   Exelixis
    Recruiting

  • Conditions:   Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Selected Tumors With Rhabdoid Features;   Synovial Sarcoma;   INI1-negative Tumors;   Malignant Rhabdoid Tumor of Ovary;   Renal Medullary Carcinoma;   Epithelioid Sarcoma;   Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval);   Any Solid Tumor With an EZH2 GOF Mutation
    Intervention:   Drug: Tazemetostat
    Sponsor:   Epizyme, Inc.
    Recruiting

  • Conditions:   Hepatocellular Carcinoma;   Metastatic Castration Resistant Prostate Cancer;   Renal Cell Carcinoma;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Squamous Cell Carcinoma of Head and Neck;   Triple-Negative Breast Cancer;   Urothelial Carcinoma;   Cholangiocarcinoma;   GastroEsophageal Cancer;   Pancreatic Cancer;   Sarcoma
    Interventions:   Drug: Part 1 TPST-1120;   Drug: Part 2a TPST-1120 + nivolumab;   Drug: Part 2b TPST-1120 + docetaxel;   Drug: Part 2c TPST-1120 + cetuximab;   Drug: Part 3 TPST-1120;   Drug: Part 4a TPST-1120 + nivolumab;   Drug: Part 4b TPST-1120 + docetaxel;   Drug: Part 4c TPST-1120 + cetuximab
    Sponsor:   Tempest Therapeutics
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer
    Interventions:   Drug: AB154;   Drug: AB122
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Conditions:   Colorectal Cancer;   Non-small Cell Lung Cancer;   Triple Negative Breast Cancer;   Renal Cell Carcinoma;   Gastric Cancer;   Pancreatic Cancer;   Urothelial Cancer
    Intervention:   Biological: GEN1029 (HexaBody®-DR5/DR5)
    Sponsor:   Genmab
    Recruiting

  • Conditions:   Metastatic Cancer;   Recurrent Cancer;   Solid Tumor;   Renal Cell Carcinoma;   Urothelial Carcinoma;   NSCLC;   Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck
    Interventions:   Drug: IRX 2;   Drug: Nivolumab
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Conditions:   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
    Sponsors:   Emory University;   Children's Healthcare of Atlanta
    Recruiting

  • Conditions:   Colorectal Cancer Metastatic;   Triple Negative Breast Cancer;   Non Small Cell Lung Cancer;   Bladder Cancer;   GastroEsophageal Cancer;   Renal Cell Carcinoma;   MSI-H
    Interventions:   Biological: EDP1503;   Biological: Pembrolizumab
    Sponsors:   Evelo Biosciences, Inc.;   SCRI Development Innovations, LLC;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Melanoma;   Merkel Cell Carcinoma;   Triple Negative Breast Cancer;   Ovarian Cancer;   Renal Cell Carcinoma;   Colorectal Cancer;   Urothelial Carcinoma;   Sarcoma
    Interventions:   Drug: NKTR-262;   Drug: NKTR-214;   Drug: nivolumab
    Sponsor:   Nektar Therapeutics
    Recruiting

  • Conditions:   Squamous Cell Carcinoma of Head and Neck;   Non-small Cell Lung Cancer;   Hepatocellular Carcinoma;   Esophageal Cancer;   Gastric Cancer;   Melanoma;   Renal Cell Carcinoma;   Pancreatic Cancer;   Cervical Cancer;   Triple Negative Breast Cancer;   Advanced Cancer
    Interventions:   Drug: KY1044;   Drug: KY1044 and atezolizumab
    Sponsor:   Kymab Limited
    Recruiting

  • Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab
    Sponsor:   Fate Therapeutics
    Recruiting

  • Conditions:   Lung Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell;   Malignant Mesothelioma, Advanced;   Head and Neck Cancer;   Melanoma;   Merkel Cell Carcinoma;   Renal Cell Carcinoma;   Urothelial Carcinoma;   Classical Hodgkin Lymphoma;   Colorectal Cancer;   Cutaneous Squamous Cell Carcinoma;   Non Hodgkin Lymphoma;   Endometrial Cancer
    Intervention:   Drug: CK-301
    Sponsors:   Checkpoint Therapeutics, Inc.;   Novotech (Australia) Pty Limited
    Recruiting

  • Conditions:   Cervical Cancer;   Gastric Cancer;   Stomach Cancer;   Gastroesophageal Junction Cancer;   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma;   Uveal Melanoma;   Merkel Cell Carcinoma;   Mesothelioma;   MSI;   Non-small Cell Lung Cancer;   NSCLC;   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   RCC;   Triple-negative Breast Cancer;   Urothelial Carcinoma;   Mismatch Repair Deficiency
    Intervention:   Drug: INCAGN02390
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Advanced Melanoma;   Advanced Renal Cell Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
    Intervention:   Procedure: Biospecimen Collection
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content;   Head and Neck Cancer;   Non-small Cell Lung Cancer;   Gastric Cancer;   Esophageal Cancer;   Pancreas Cancer;   Bladder Cancer;   Renal Cell Carcinoma;   Melanoma;   Triple-negative Breast Cancer;   Ovarian Cancer
    Intervention:   Drug: ADCT-301
    Sponsor:   ADC Therapeutics S.A.
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: AB928;   Drug: AB122
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Conditions:   Squamous Cell Carcinoma of the Head and Neck;   Melanoma;   Non Small Cell Lung Cancer;   Urothelial Carcinoma;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Squamous Cell Carcinoma of the Anus;   Squamous Cell Carcinoma of the Cervix;   Squamous Cell Carcinoma of the Skin;   Renal Cell Carcinoma;   Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Mismatch Repair Deficient or MSI-High Solid Tumors
    Intervention:   Drug: SL-279252
    Sponsor:   Shattuck Labs, Inc.
    Recruiting

  • Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer
    Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
    Sponsor:   Fate Therapeutics
    Recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Synovial Sarcoma;   Epitheliod Sarcoma;   Mesothelioma;   Advanced Solid Tumors
    Intervention:   Drug: Tazemetostat
    Sponsor:   Epizyme, Inc.
    Recruiting

  • Conditions:   Solid Tumor;   Clear Cell Renal Cell Carcinoma;   TNBC - Triple-Negative Breast Cancer;   Colorectal Cancer;   CRC;   RCC;   ccRCC
    Interventions:   Drug: CB-839;   Drug: Talazoparib
    Sponsor:   Calithera Biosciences, Inc
    Recruiting

  • Conditions:   NSCLC, Non Small Cell Lung Cancer;   RCC, Renal Cell Cancer;   Pancreatic Cancer;   Urothelial Cancer;   Head and Neck Cancer;   DLBCL, Diffused Large B Cell Lymphoma;   MSS, Microsatellite Stable Colon Cancer;   TNBC, Triple Negative Breast Cancer;   Melanoma
    Interventions:   Drug: NIR178;   Drug: PDR001
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   HER2-positive Breast Cancer;   HER2 Gene Mutation;   HER-2 Gene Amplification;   HER2 Positive Gastric Cancer;   Salivary Gland Cancer;   Salivary Gland Tumor;   Salivary Gland Carcinoma;   Salivary Gland Neoplasms;   Lung Cancer;   Colo-rectal Cancer;   Rare Diseases;   Solid Tumor;   Recurrent Gastric Cancer;   Recurrent Colon Cancer;   Recurrent Breast Cancer;   Head and Neck Cancer;   Head and Neck Carcinoma;   Bladder Cancer;   Cervical Cancer;   Liver Cancer;   Bile Duct Cancer;   Urologic Cancer;   Pancreatic Cancer;   Prostate Cancer;   Recurrent Prostate Cancer;   Rectal Cancer;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Cancer;   Rectal Cancer Stage II;   Rectal Cancer Stage I;   Rectal Cancer Stage III;   Skin Cancer;   Mouth Cancer;   Lip Cancer Stage I;   Tongue Cancer;   Breast Neoplasm Malignant Primary;   Larynx Cancer;   Tonsil Cancer;   Palate Cancer;   Mucoepidermoid Carcinoma;   Primary Peritoneal Carcinoma;   Mucinous Adenocarcinoma Gastric;   Mucinous Breast Cancer Recurrent;   Cholangiocarcinoma
    Intervention:   Drug: A166
    Sponsor:   Klus Pharma Inc.
    Recruiting

  • Conditions:   Cervical Cancer;   Microsatellite Instability (MSI)-High Endometrial Cancer;   Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]);   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma (Uveal Melanoma Excluded);   Merkel Cell Carcinoma;   Mesothelioma;   MSI-high Colorectal Cancer;   Non-small Cell Lung Cancer (NSCLC);   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Small Cell Lung Cancer (SCLC);   Renal Cell Carcinoma (RCC);   Triple-negative Breast Cancer;   Urothelial Carcinoma;   Diffuse Large B-cell Lymphoma
    Intervention:   Biological: INCAGN02385
    Sponsor:   Incyte Biosciences International Sàrl
    Recruiting

  • Conditions:   Metastatic Cancer;   Solid Tumors;   Colorectal Cancer (CRC);   Gastric Cancer;   Head and Neck Cancer;   Lung Cancer;   Renal Cell Carcinoma (RCC);   Bladder Cancer;   UC (Urothelial Cancer);   Mesothelioma
    Interventions:   Drug: INCB001158;   Drug: Pembrolizumab
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Colorectal Cancer (CRC);   Endometrial Cancer;   Melanoma;   Head and Neck Cancer;   Lung Cancer;   MMR-deficient Tumors;   Breast Cancer;   Pancreatic Cancer;   Renal Cell Carcinoma (RCC);   Solid Tumors;   UC (Urothelial Cancer)
    Interventions:   Drug: Pembrolizumab;   Drug: itacitinib;   Drug: INCB050465
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Mesothelioma;   Bladder Cancer;   Melanoma;   Squamous Cell Carcinoma of the Head and Neck;   Non Small Cell Lung Cancer;   Clear Cell Renal Cell Carcinoma;   Ovarian Cancer;   Thyroid Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer;   Colon Cancer;   Soft Tissue Sarcoma
    Intervention:   Biological: MGD009
    Sponsor:   MacroGenics
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Brain Glioblastoma;   Estrogen Receptor Negative;   Extensive Stage Small Cell Lung Carcinoma;   Head and Neck Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Limited Stage Small Cell Lung Carcinoma;   Myelodysplastic Syndrome;   Progesterone Receptor Negative;   Progressive Disease;   Recurrent Carcinoma;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage III Colon Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage III Ovarian Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Skin Melanoma;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Bone Sarcoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IV Soft Tissue Sarcoma;   Stage IVA Bone Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Bone Sarcoma;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Procedure: Supportive Care;   Other: Survey Administration
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Carcinoma of Unknown Primary Origin;   Kidney Medullary Carcinoma;   Malignant Germ Cell Tumor;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Paraganglioma;   Metastatic Penile Carcinoma;   Paraganglioma;   Skin Squamous Cell Carcinoma;   Small Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Solid Neoplasm;   Vascular Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Urothelial Carcinoma AJCC v7
    Interventions:   Drug: ATR Kinase Inhibitor M6620;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Urothelial Carcinoma Bladder;   Urothelial Carcinoma Ureter;   Urothelial Carcinoma of the Renal Pelvis and Ureter;   Urothelial Carcinoma Urethra
    Interventions:   Drug: Sitravatinib;   Drug: Nivolumab
    Sponsor:   Mirati Therapeutics Inc.
    Recruiting

  • Condition:   Solid Cancer
    Intervention:   Drug: BAY73-4506 (Regorafenib, Stivarga)
    Sponsor:   Bayer
    Not yet recruiting

  • Condition:   Renal Cyst Complex
    Intervention:   Diagnostic Test: Radiomics
    Sponsors:   Maastricht University;   University of California, San Francisco;   Stanford University;   Erasmus Medical Center;   Memorial Sloan Kettering Cancer Center;   University of Sao Paulo General Hospital;   University Hospital, Aachen
    Recruiting

  • Conditions:   Metastatic Urothelial Carcinoma;   Recurrent Bladder Urothelial Carcinoma;   Recurrent Urethral Urothelial Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Renal Pelvis Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma
    Interventions:   Drug: Atezolizumab;   Drug: Eribulin Mesylate;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage III Bladder Urothelial Carcinoma;   Stage III Urethral Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Urethral Cancer;   Urethral Urothelial Carcinoma
    Interventions:   Drug: Pembrolizumab;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride
    Sponsors:   University of California, Davis;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Advanced Solid Tumors
    Intervention:   Drug: TAS-102
    Sponsor:   Taiho Oncology, Inc.
    Recruiting

  • Conditions:   Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall;   Stage II Bladder Cancer AJCC v8;   Stage II Renal Pelvis Cancer AJCC v8;   Stage II Ureter Cancer AJCC v8;   Stage II Urethral Cancer AJCC v8;   Stage III Bladder Cancer AJCC v8;   Stage III Renal Pelvis Cancer AJCC v8;   Stage III Ureter Cancer AJCC v8;   Stage III Urethral Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8;   Stage IIIB Bladder Cancer AJCC v8;   Urethral Urothelial Carcinoma
    Interventions:   Drug: Avelumab;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Mitomycin;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urothelial Carcinoma;   High Grade Serous Carcinoma;   Endometrioid Adenocarcinoma;   Urothelial Carcinoma Bladder;   Urothelial Carcinoma Ureter Regional;   Urothelial Carcinoma Ureter Metastatic;   Urothelial Carcinoma Ureter Local;   Urothelial Carcinoma Bladder Recurrent;   Urothelial Carcinoma of the Renal Pelvis and Ureter;   Urothelial Carcinoma Ureter
    Interventions:   Drug: Rucaparib;   Drug: Nivolumab
    Sponsors:   Clovis Oncology, Inc.;   Bristol-Myers Squibb;   Foundation Medicine
    Not yet recruiting

  • Conditions:   Hydronephrosis;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant;   Renal Pelvis Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage II Renal Pelvis Cancer AJCC v7;   Stage II Ureter Cancer AJCC v7;   Stage II Urethral Cancer AJCC v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Biological: Durvalumab;   Procedure: Therapeutic Conventional Surgery;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Healthy Control;   Localized Urothelial Carcinoma of the Renal Pelvis and Ureter;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Bladder Urothelial Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Urothelial Carcinoma;   Recurrent Renal Pelvis Urothelial Carcinoma;   Recurrent Ureter Urothelial Carcinoma;   Recurrent Urethral Urothelial Carcinoma;   Stage III Bladder Cancer AJCC v8;   Stage III Renal Pelvis Cancer AJCC v8;   Stage III Ureter Cancer AJCC v8;   Stage III Urethral Cancer AJCC v8;   Stage IV Bladder Cancer AJCC v8;   Stage IV Renal Pelvis Cancer AJCC v8;   Stage IV Ureter Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8
    Interventions:   Drug: Atezolizumab;   Biological: Glycosylated Recombinant Human Interleukin-7;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer of Unknown Origin;   Cancer Refractory;   Cancer of Stomach;   Cancer Head Neck;   Cancer of Skin;   Cancer, Lung;   Cancer Colorectal;   Cancer of Esophagus;   Cancer, Bladder;   Cancer, Uterus;   Cancer Cervix;   Cancer Liver;   Cancer, Kidney;   Cancer, Breast;   Hematologic Neoplasms
    Intervention:   Other: Genomic testing
    Sponsors:   Arbeitsgemeinschaft medikamentoese Tumortherapie;   Roche Pharma AG
    Recruiting

  • Condition:   Brain Metastases
    Interventions:   Radiation: Whole brain radiation;   Radiation: Stereotactic radiation (SRS)
    Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital
    Recruiting

  • Condition:   Digestive System Neoplasms
    Intervention:   Device: EUS-guided RFA
    Sponsor:   Chinese University of Hong Kong
    Recruiting

  • Condition:   Advanced Solid Tumor
    Interventions:   Drug: Pembrolizumab;   Drug: Trebananib
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.;   Amgen
    Recruiting

  • Condition:   Cancer Patients Receiving Stereotactic Body RTX
    Intervention:   Radiation: SBRT
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Conditions:   Esophageal Neoplasms;   Lung Neoplasms;   Mesothelioma;   Thymus Neoplasms;   Neoplasms, Germ Cell and Embryonal
    Intervention:   Drug: Mithramycin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Carcinoma, Renal Cell;   Carcinoma, Urothelial
    Intervention:   Device: Immune cell and CTC detection procedures
    Sponsors:   Duke University;   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Carcinoma, Renal Cell;   Head and Neck Neoplasm;   Skin Neoplasms;   Microsatellite Instability;   Penile Neoplasms
    Intervention:   Drug: Nivolumab
    Sponsors:   UNICANCER;   National Cancer Institute, France;   Ligue contre le cancer, France;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma;   Extra Renal Origin;   Clear Cell Adenocarcinoma
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Don Dizon;   Bristol-Myers Squibb;   Rhode Island Hospital;   The Miriam Hospital;   Brown University
    Recruiting

  • Conditions:   Advanced Malignancies;   Metastatic Cancer
    Intervention:   Drug: INCAGN01876
    Sponsor:   Incyte Biosciences International Sàrl
    Recruiting

  • Condition:   Solid Tumors
    Intervention:   Drug: Avelumab
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Not yet recruiting

  • Conditions:   Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Melanoma;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma;   Pancreatic Neoplasms;   Ovarian Neoplasms;   Carcinoma, Renal Cell;   Cholangiocarcinoma;   Skin Carcinoma;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms, Nerve Tissue;   Nevi and Melanomas;   Intestinal Neoplasms;   Thyroid Cancer;   GIST;   Malignant Peripheral Nerve Sheath Tumors;   Breast Secretory Carcinoma;   Uterine Neoplasms;   Fibrosarcoma;   Infantile Fibrosarcoma;   Congenital Mesoblastic Nephroma;   Central Nervous System Neoplasms
    Intervention:   Drug: LOXO-195
    Sponsors:   Loxo Oncology, Inc.;   Bayer
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   RB1 Positive;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Pediatric Solid Tumor;   Germ Cell Tumor;   Retinoblastoma;   Hepatoblastoma;   Wilms Tumor;   Rhabdoid Tumor;   Carcinoma;   Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Synovial Sarcoma;   Clear Cell Sarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Desmoplastic Small Round Cell Tumor;   Soft Tissue Sarcoma;   Neuroblastoma
    Interventions:   Biological: second generation 4-1BBζ EGFR806-EGFRt;   Biological: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
    Sponsor:   Seattle Children's Hospital
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   ARAF Gene Mutation;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   HRAS Gene Mutation;   KRAS Gene Mutation;   MAP2K1 Gene Mutation;   MAPK1 Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   0.5-14 Year Old Children With Nephroblastoma
    Interventions:   Drug: Vincristine;   Drug: Oxytetracycline/ Cyclophosphamide;   Drug: Liposomal doxorubicin;   Drug: Doxorubicin;   Drug: Pharmorubicin;   Drug: Pirarubicin
    Sponsor:   Shengjing Hospital
    Not yet recruiting

  • Conditions:   Wilms' Tumor;   Aniridia
    Interventions:   Behavioral: Questionnaire;   Other: Blood specimen
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Deleterious ATM Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Deleterious RAD51C Gene Mutation;   Deleterious RAD51D Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF NP_004324.2:p.V600X;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Histiocytosis;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   TSC1 Gene Mutation;   TSC2 Gene Mutation;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Malignant Glioma;   NTRK1 Fusion Positive;   NTRK2 Fusion Positive;   NTRK3 Fusion Positive;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pediatric Cancer;   Solid Tumors;   Rhabdomyosarcoma;   Ewing Sarcoma;   Soft Tissue Sarcomas;   Osteosarcoma;   Neuroblastoma;   Wilms Tumor;   Hepatic Tumor;   Germ Cell Tumors
    Interventions:   Device: Magnetic resonance high intensity focused ultrasound;   Drug: Lyso-thermosensitive liposomal doxorubicin
    Sponsor:   AeRang Kim
    Recruiting

  • Conditions:   Glioma;   Rhabdomyosarcoma;   Osteosarcoma;   Medulloblastoma;   Neuroectodermal Tumor;   Ependymoma;   Ewing's Sarcoma;   Wilms Tumor
    Interventions:   Biological: Erlotinib;   Drug: Temozolomide
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Childhood Langerhans Cell Histiocytosis;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Central Nervous System Neoplasm;   Childhood Immature Teratoma;   Childhood Langerhans Cell Histiocytosis;   Childhood Malignant Neoplasm;   Childhood Mature Teratoma;   Congenital Mesoblastic Nephroma;   Desmoid-Type Fibromatosis;   Lymphoproliferative Disorder;   Myeloproliferative Neoplasm;   Stromal Neoplasm
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Medical Chart Review
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Glioma;   Neuroectodermal Tumors, Primitive;   Wilms Tumor;   Rhabdomyosarcoma;   Sarcoma, Ewing;   Osteosarcoma;   Retinoblastoma
    Interventions:   Drug: Metronomic Cyclophosphamide;   Drug: Thalidomide
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Gait, Drop Foot;   Chemotherapy-induced Peripheral Neuropathy;   Acute Lymphocytic Leukemia, Pediatric;   Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Device: Solid ankle foot orthotic;   Device: Resting night splint
    Sponsors:   Children's Hospitals and Clinics of Minnesota;   Pine Tree Apple Tennis Classic Foundation;   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Pancreatic Ca;   Colon/ Rectal Ca;   Multiple Myeloma;   Carcinoma, Non-Small -Cell Lung
    Interventions:   Drug: NK cells +CliniMACs CD3 and CD56 systems;   Biological: NK cells
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Advanced Malignancies
    Interventions:   Drug: MBG453;   Drug: PDR001
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Malignant Neoplasms
    Interventions:   Drug: RGX-104;   Drug: Nivolumab
    Sponsor:   Rgenix, Inc.
    Recruiting

  • Condition:   Advanced Cancer
    Intervention:   Drug: MGCD516
    Sponsor:   Mirati Therapeutics Inc.
    Recruiting

  • Conditions:   Advanced Malignancies;   Metastatic Cancer
    Interventions:   Drug: INCAGN01876;   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsor:   Incyte Biosciences International Sàrl
    Recruiting

  • Condition:   Neoplasms
    Interventions:   Drug: GSK3359609;   Drug: Tremelimumab;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Cetuximab
    Sponsors:   GlaxoSmithKline;   MedImmune LLC
    Recruiting

  • Conditions:   Prostate Cancer;   Benign Prostatic Hypertrophy;   Bladder Stones;   Kidney Stones
    Intervention:   Diagnostic Test: NV-VPAC1 PCa Urine Diagnostic Test
    Sponsors:   Intermountain Health Care, Inc.;   NuView Diagnostics
    Recruiting

  • Conditions:   Immunocompromised Host;   Organ Transplantation;   Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-melanoma Skin Cancer
    Interventions:   Drug: UAB30;   Drug: Placebo
    Sponsor:   University of Alabama at Birmingham
    Not yet recruiting

  • Condition:   Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
    Intervention:   Drug: Regorafenib
    Sponsors:   University of Alabama at Birmingham;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
    Recruiting